[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucosylceramide-beta-glucosidase-deficiency-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucosylceramide-beta-glucosidase-deficiency-disease":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100084590",false,"NCT00358943","International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","Gaucher Disease Registry Protocol","Inclusion Criteria:\n\nICGG Gaucher Registry\n\n* All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and\u002For mutation in the β-glucocerebrosidase gene.\n* For all patients, appropriate patient authorization will be obtained.\n\nGaucher Pregnancy Sub-registry:\n\n* be enrolled in the ICGG Gaucher Registry.\n* be pregnant, or have been pregnant with appropriate medical documentation available.\n* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.\n\nExclusion Criteria:\n\n\\- No exclusion criteria for participation in the ICGG Gaucher Registry and Sub-registry.","ALL",{"count":17,"type":18},12000,"ESTIMATED","12 Months","OBSERVATIONAL","The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Gaucher disease population.\n* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.\n\nGaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.",[23,24,25,26],"Gaucher Disease","Cerebroside Lipidosis Syndrome","Glucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease",[23,25],"RECRUITING","2026-04-13",{"date":31,"type":32},"2026-04-14","ACTUAL",{"date":34,"type":32},"1991-04-01",{"date":36,"type":18},"2034-01-31",{"name":38,"class":39},"Genzyme, a Sanofi Company","INDUSTRY",318,""]